NCT00499655View on ClinicalTrials.gov

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

DRUG

celecoxib

Given orally

OTHER

placebo

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

GENETIC

fluorescence in situ hybridization

Correlative studies

GENETIC

mutation analysis

Correlative studies

GENETIC

protein expression analysis

Correlative studies

GENETIC

gene expression analysis

Correlative studies

Trial Locations (2)

91010

City of Hope Medical Center, Duarte

91030

South Pasadena Cancer Center, South Pasadena

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

City of Hope Medical Center

OTHER